Patents Represented by Attorney Human Genome Sciences, Inc.
-
Patent number: 7029870Abstract: The present invention relates to a novel GABAA receptor ? subunit (GABRE) and an alternative transcript thereof (ET2). More specifically, isolated nucleic acid molecules are provided encoding human GABRE and ET2 receptor subunits. ET2 and GABRE polypeptides are also provided, as are vectors, host cells and recombinant methods for producing the same. The invention further relates to screening methods for identifying agonists and antagonists of ET2 and GABRE activities. Also provided are diagnostic methods for detecting aberrant GABRE and ET2 expression, as well as therapeutic methods for treating disorders involving ET2 and GABRE.Type: GrantFiled: February 26, 1998Date of Patent: April 18, 2006Assignee: Human Genome Sciences, Inc.Inventors: Michael C. Hanna, Ewen F. Kirkness
-
Patent number: 7026299Abstract: The present invention relates to a human CTGF-2 polypeptide and DNA (RNA) encoding such polypeptide. Also provided is a procedure for producing such polypeptide by recombinant techniques and antibodies and antagonist/inhibitors against such polypeptide. Also provided are methods of using the polypeptide therapeutically for stimulating angiogenesis enhancing the repair of connective and support tissue, promoting the attachment, fixation and stabilization of tissue implants and enhancing wound healing. Diagnostic assays for identifying mutations in nucleic acid sequence encoding a polypeptide of the present invention and for detecting altered levels of the polypeptide of the present invention are also disclosed.Type: GrantFiled: July 11, 2001Date of Patent: April 11, 2006Assignees: Human Genome Sciences, Inc., Transgene S.A.Inventors: Haodong Li, Mark D. Adams, Valérie Calenda, Virginie Fataccioli
-
Patent number: 7026447Abstract: The present invention relates to novel human secreted proteins and isolated nucleic acids containing the coding regions of the genes encoding such proteins. Also provided are vectors, host cells, antibodies, and recombinant methods for producing human secreted proteins. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating diseases, disorders, and/or conditions related to these novel human secreted proteins.Type: GrantFiled: October 30, 2001Date of Patent: April 11, 2006Assignee: Human Genome Sciences, Inc.Inventors: Craig A. Rosen, Steven M. Ruben, Charles Florence
-
Patent number: 7026140Abstract: Human serum paraoxonase enzyme and DNA (RNA) encoding such serum paraoxonase enzymes are disclosed. Also provided is the procedure for producing such polypeptides by recombinant techniques. Uses of such polypeptides include their use as an antidote for organophosphate poisoning and to prevent neuronal cell death.Type: GrantFiled: September 2, 2004Date of Patent: April 11, 2006Assignee: Human Genome Sciences, Inc.Inventors: Peter L. Hudson, Wei Wu He, Steven M. Ruben
-
Patent number: 7012134Abstract: The present invention relates to a novel human protein called Dendritic Enriched Secreted Lymphocyte Activation Molecule, and isolated polynucleotides encoding this protein. Also provided are vectors, host cells, antibodies, and recombinant methods for producing this human protein. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating disorders related to this novel human protein.Type: GrantFiled: February 5, 2002Date of Patent: March 14, 2006Assignee: Human Genome Sciences, Inc.Inventors: Steven M. Ruben, Paul E. Young
-
Patent number: 7008778Abstract: The present invention relates to a novel BCSG1 protein. In particular, isolated nucleic acid molecules are provided encoding the human BCSG1 protein. BCSG1 polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same. Also provided are diagnostic methods for detecting breast cancer.Type: GrantFiled: February 3, 1998Date of Patent: March 7, 2006Assignee: Human Genome Sciences, Inc.Inventors: Hongjun Ji, Craig A. Rosen
-
Patent number: 7001992Abstract: The present invention relates to novel human secreted proteins and isolated nucleic acids containing the coding regions of the genes encoding such proteins. Also provided are vectors, host cells, antibodies, and recombinant methods for producing human secreted proteins. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating disorders related to these novel human secreted proteins.Type: GrantFiled: February 5, 2002Date of Patent: February 21, 2006Assignee: Human Genome Sciences, Inc.Inventors: Steven M. Ruben, Craig A. Rosen, Gregory A. Endress
-
Patent number: 7001595Abstract: The present invention relates to deletion and substitution mutant polypeptides of human chemokine ?-7 (Ck?-7), as well as nucleic acid molecules encoding such polypeptides and processes for producing such polypeptides using recombinant techniques. In one aspect, the invention also relates to uses of the full-length and mature forms of Ck?-7, as well as deletion and substitution mutants, in medical treatment regimens. In particular, the Ck?-7 polypeptides described herein may be employed to treat a variety of conditions, including rheumatoid arthritis, inflammation, respiratory diseases, allergy, and IgE-mediated allergic reactions.Type: GrantFiled: October 1, 2002Date of Patent: February 21, 2006Assignees: Human Genome Sciences Inc., Beatson Institute for Cancer ResearchInventors: Theodora W. Salcedo, Vikram P. Patel, Robert John Benjamin Nibbs, Gerard John Graham
-
Patent number: 6994978Abstract: Disclosed is a human osteoclast-derived cathepsin (Cathepsin O) polypeptide and DNA(RNA) encoding such cathepsin O polypeptides. Also provided is a procedure for producing such polypeptide by recombinant techniques. The present invention also discloses antibodies, antagonists and inhibitors of such polypeptide which may be used to prevent the action of such polypeptide and therefore may be used therapeutically to treat bone diseases such as osteoporosis and cancers, such as tumor metastases.Type: GrantFiled: December 4, 2003Date of Patent: February 7, 2006Assignees: Human Genome Sciences, Inc., SmithKline Beecham CorporationInventors: Gregg A. Hastings, Mark D. Adams, Claire M. Fraser, Norman H. Lee, Ewen F. Kirkness, Judith A. Blake, Lisa M. Fitzgerald, Fred H. Drake, Maxine Gowan
-
Patent number: 6982320Abstract: The present invention relates to a novel human protein called Cytokine Receptor Common Gamma Chain Like, and isolated polynucleotides encoding this protein. Also provided are vectors, host cells, antibodies, and recombinant methods for producing this human protein. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating disorders related to this novel human protein.Type: GrantFiled: August 18, 1999Date of Patent: January 3, 2006Assignee: Human Genome Sciences, Inc.Inventors: Paul A. Moore, Craig A. Rosen, Steven M. Ruben
-
Patent number: 6979443Abstract: The present invention relates to a novel CK?-6 protein which is a member of the alpha chemokine family. In particular, isolated nucleic acid molecules are provided encoding the human CK?-6 protein. CK?-6 polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same. The invention further relates to screening methods for identifying agonists and antagonists of CK?-6 activity. Also provided are diagnostic methods for detecting CNS and immune system-related disorders and therapeutic methods for treating CNS and immune system-related disorders.Type: GrantFiled: March 4, 2002Date of Patent: December 27, 2005Assignee: Human Genome Sciences, Inc.Inventors: Ying-Fei Wei, Steven M. Ruben, Craig A. Rosen
-
Patent number: 6974682Abstract: The present invention relates to a novel soluble IL-1 receptor accessory molecule (IL-1R AcM) protein which is a member of the Ig superfamily. In particular, isolated nucleic acid molecules are provided encoding the human IL-1R AcM protein IL-1R AcM polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same. Screening methods are further provided for identifying agonist and antagonists of IL-1 signal transduction. The invention further relates to methods for treating physiologic and pathologic disease conditions with IL-1R AcM antagonists.Type: GrantFiled: August 26, 1997Date of Patent: December 13, 2005Assignee: Human Genome Sciences, Inc.Inventors: Daniel P. Bednarik, Henrik S. Olsen, Craig A. Rosen
-
Patent number: 6969519Abstract: The present invention relates to a novel protein, TR17, which is a member of the tumor necrosis factor (TNF) receptor superfamily. In particular, isolated nucleic acid molecules are provided encoding the human TR17. TR17 polypeptides are also provided as anti TR17 antibodies and vectors, host cells and recombinant methods for producing the same. The invention further relates to methods of killing cells using the antibodies of the invention.Type: GrantFiled: September 25, 2001Date of Patent: November 29, 2005Assignee: Human Genome Sciences, Inc.Inventors: Steven M. Ruben, Kevin P. Baker
-
Patent number: 6969599Abstract: The present invention relates to a novel protein, TR10, which is a member of the tumor necrosis factor (TNF) receptor superfamily and the TRAIL receptor subfamily. In particular, isolated nucleic acid molecules are provided encoding the human TR10 protein. TR10 polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same. The invention further relates to screening methods for identifying agonists and antagonists of TR10 activity.Type: GrantFiled: October 25, 2002Date of Patent: November 29, 2005Assignee: Human Genome Sciences, Inc.Inventors: Jian Ni, Craig A. Rosen
-
Patent number: 6955885Abstract: A human stanniocalcin-alpha polypeptide and DNA (RNA) encoding such polypeptide and a procedure for producing such polypeptide by recombinant techniques is disclosed. Also disclosed are methods for utilizing such polypeptide for the regulation of electrolyte imbalances which can lead to renal, bone and heart diseases and osteoporosis and Paget's Disease. Antagonists against such polypeptides and their use in the regulation of electrolyte imbalances which can lead to hypocalcemia and osteoporosis are also disclosed. Use of the stanniocalcin-alpha sequence as a diagnostic to detect diseases or the susceptibility to diseases related to a mutated form of stanniocalcin-alpha sequences is also disclosed.Type: GrantFiled: April 18, 2003Date of Patent: October 18, 2005Assignee: Human Genome Sciences, Inc.Inventors: Henrik S. Olsen, Robert D. Fleischmann
-
Patent number: 6953662Abstract: The present invention relates to a novel follistatin-3 protein which is a member of the family of inhibin-related proteins. In particular, isolated nucleic acid molecules are provided encoding the human follistatin-3 protein. Follistatin-3 polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same. The invention further relates to screening methods for identifying agonists and antagonists of follistatin-3 activity. Also provided are diagnostic methods for detecting reproductive system-related disorders and disorders of the regulation of cell growth and differentiation and therapeutic methods for treating reproductive system-related disorders and disorders of the regulation of cell growth and differentiation.Type: GrantFiled: February 26, 2003Date of Patent: October 11, 2005Assignee: Human Genome Sciences, Inc.Inventors: D. Roxanne Duan, Steven M. Ruben
-
Patent number: 6953667Abstract: The present invention relates to novel human secreted proteins and isolated nucleic acids containing the coding regions of the genes encoding such proteins. Also provided are vectors, host cells, antibodies, and recombinant methods for producing human secreted proteins. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating diseases, disorders, and/or conditions related to these novel human secreted proteins.Type: GrantFiled: January 25, 2002Date of Patent: October 11, 2005Assignee: Human Genome Sciences, Inc.Inventors: Paul A. Moore, Steven M. Ruben, Henrik S. Olsen, Yanggu Shi, Craig A. Rosen, Kimberly A. Florence, Daniel R. Soppet, David W. LaFleur, Gregory A. Endress, Reinhard Ebner, George Komatsoulis, Roxanne D. Duan
-
Patent number: 6951738Abstract: The present invention relates to two novel proteins, TR13 and TR14, which are members of the tumor necrosis factor (TNF) receptor superfamily. In particular, isolated nucleic acid molecules are provided encoding the human TR13 and TR14 proteins. TR13 and TR14 polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same. The invention further relates to screening methods for identifying agonists and antagonists of TR13 and TR14.Type: GrantFiled: January 16, 2002Date of Patent: October 4, 2005Assignee: Human Genome Sciences, Inc.Inventors: Jian Ni, Kevin P. Baker, Steven M. Ruben, Paul E. Young
-
Patent number: 6951924Abstract: The present invention relates to novel human secreted proteins and isolated nucleic acids containing the coding regions of the genes encoding such proteins. Also provided are vectors, host cells, antibodies, and recombinant methods for producing human secreted proteins. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating diseases, disorders, and/or conditions related to these novel human secreted proteins.Type: GrantFiled: January 30, 2002Date of Patent: October 4, 2005Assignee: Human Genome Sciences, Inc.Inventors: Craig A. Rosen, Steven M. Ruben, ZhiZhen Zeng
-
Patent number: 6951735Abstract: The present invention relates to novel Death Domain Containing Receptor (DR3 and DR3-V1) proteins which are members of the tumor necrosis factor (TNF) receptor family. In particular, isolated nucleic acid molecules are provided encoding the human DR3 and DR3-V1 proteins. DR3 and DR3-V1 polypeptides are also provided, as are vectors, host cells and recombinant methods for producing the same. The invention further relates to screening methods for identifying agonists and antagonists of DR3 and DR3-V1 activity.Type: GrantFiled: May 19, 1999Date of Patent: October 4, 2005Assignees: Human Genome Sciences, Inc., The Regents of the University of MichiganInventors: Guo-Liang Yu, Jian Ni, Vishva Dixit, Reiner L. Gentz, Patrick J. Dillon